Kailera Therapeutics said its obesity drug met efficacy goals in late-stage China trials, reporting about 10% weight loss over 10 months. The company’s data also showed high rates of gastrointestinal side effects that “alarmed” an analyst, underscoring the trade-off typically emphasized in oral GLP-1 programs. The results were tied to ongoing regulatory planning via partner Hengrui Pharma, with the sponsor seeking approval in both obesity and diabetes. For sponsors, the update shifts focus to tolerability, discontinuation risk, and real-world adherence considerations. While primary endpoints were reported as achieved, the safety profile will likely influence label language and launch strategy.